Adherence and Growth Outcomes in a Large Cohort of Children Treated With Recombinant GH Using a Connected Auto-injector

Authors:

Abstract
Context: Adherence to recombinant GH treatment is crucial to achieve optimal adult height in children with growth disorders. Information on factors responsible for differences in adherence and growth in different countries is limited. Aim: To evaluate adherence and catch-up growth in children receiving GH using Easypod® auto-injectors. Methods: Retrospective cohort analysis of adherence and height, from 481 children (55% boys) in 19 centers in France, from the Growzen® Connect database, from mid-2018 to end-2023. Adherence was classified as high (≥85% of injections) or medium/low ( .5). For children with high adherence, 2-year HSDS gain was significantly higher than for children with lower adherence (0.8 vs +0.5, P = .030). Conclusion: Children using Easypod exhibit high adherence, which aids clinical decision-making and patient engagement. Adherence and catch-up growth decrease with age. Indication for GH treatment had little impact, but overall catch-up growth was significantly greater with high adherence.
Funding Information
  • Merck KGaA

This publication has 41 references indexed in Scilit: